GlassScriptPhysician profile
Reza Mojtabavi
NPI 1225152598
$3,758.69
in general payments reported to CMS, 2019-2025
31 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $482 · 2021: $497 · 2022: $615 · 2023: $771 · 2024: $311 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $586.61 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $446.69 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $347.70 | 2020-2023 | Verquvo, Janumet, Januvia |
| Novo Nordisk INC | $289.34 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $242.07 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $221.02 | 2019-2020 | |
| Amgen INC. | $219.78 | 2021-2025 | Otezla, Repatha, Otezla |
| Corcept Therapeutics | $178.01 | 2022-2023 | Korlym |
| Abbvie INC. | $154.51 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.51 | 2019 | |
| Glaxosmithkline, LLC. | $115.92 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $111.31 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $99.24 | 2019-2020 | |
| Intuitive Surgical, INC. | $82.04 | 2024 | |
| Almatica Pharma LLC | $74.22 | 2023 | Gralise, Loreev Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.67 | 2019-2025 | Jardiance |
| Genentech USA, INC. | $60.57 | 2019-2022 | |
| Pfizer INC. | $55.47 | 2022-2024 | |
| Amarin Pharma, INC. | $47.67 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $42.38 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $42.34 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.64 | 2022 | |
| Abbott Laboratories | $17.70 | 2021 | |
| Lucid Diagnostics INC. | $17.57 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.68 | 2021 | |
| Bardy Diagnostics, INC. | $14.60 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.16 | 2021 | |
| Insulet Corporation | $12.84 | 2020 | |
| Daiichi Sankyo INC. | $12.11 | 2019 | |
| Dexcom, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Mojtabavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.